泰達生物(08189.HK)擬1059.3萬元出售上海微帝82.76%股權
格隆匯3月27日丨泰達生物(08189.HK)公吿,於2024年1月31日,公司訂立股權轉讓協議,據此,公司同意按代價人民幣1059.3萬元,向買方出售上海微帝82.76%的股權。於完成後,公司仍將持有上海微帝17.24%的股權。
鑑於上海微帝過去兩年的業績表現,以及未來前景存在不確定性,董事會認為,出售事項為公司變現其於上海微投資好機會。此外,考慮出售事項所得款項,公司能夠將其資源重新分配至現有其他經營業務,從而為其股東帶來更佳回報且亦進一步增強本集團現金流量。公司管理層亦可專注於集團生物複合肥業務和養老業務。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.